Regulatory & Compliance

FDA OKs J&J’s Icotyde, First Oral IL-23 Psoriasis Drug
Research & Development FDA OKs J&J’s Icotyde, First Oral IL-23 Psoriasis Drug

Clinic days often hinge on one question patients ask with a mix of hope and hesitation: is there a pill that can match the clearing power of injections without the needles, the storage hassles, or the crowded appointment calendar. That answer just shifted as the FDA cleared Johnson & Johnson’s

Can Flow Cytometry Reveal Cell Stiffness for Diagnosis?
Tech & Innovation Can Flow Cytometry Reveal Cell Stiffness for Diagnosis?

Hospitals needed faster answers while disease often hid in the subtle give, drag, and spring of living cells as they squeezed through microchannels and flowed past sensors that could now read mechanics at scale. That tension between urgency and nuance defined the promise of a new microfluidic

Could Manganese Contrast Replace Gadolinium in MRI?
Management & Regulatory Could Manganese Contrast Replace Gadolinium in MRI?

Growing strain on MRI services collided with sharpening concerns over safety, supply, and sustainability, forcing radiology to rethink the chemistry behind contrast enhancement at scale, where about a third of scans depend on it for clarity that shapes life-changing decisions. That collision set

How Can Mobile Devices Secure Sensitive Healthcare Data?
Tech & Innovation How Can Mobile Devices Secure Sensitive Healthcare Data?

Healthcare facilities across the United States are currently navigating an era of unprecedented digital transformation where the rapid retrieval of patient data is essential for emergency clinical decision-making. However, the convenience of using mobile tablets and smartphones at the bedside

New Regulatory Standards Accelerate Biosimilar
Management & Regulatory New Regulatory Standards Accelerate Biosimilar

The landscape of global pharmaceuticals is currently witnessing a profound architectural shift as legacy regulatory frameworks, once characterized by redundant clinical hurdles, give way to a streamlined, evidence-based approach designed to democratize access to biological therapies. For several

Can Risk-Based Oversight Secure AI in Clinical Research?
Research & Development Can Risk-Based Oversight Secure AI in Clinical Research?

The rapid proliferation of computational intelligence in pharmaceutical development has reached a critical juncture where traditional manual oversight methods are struggling to keep pace with the speed of machine learning integration. On April 20, 2026, Advarra unveiled a comprehensive framework

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later